References

  1. Criner, GJ, Sue, R, Wright, S, Dransfield, M, Rivas-Perez, H, Wiese, T & Morrissey, B. A multicenter randomized controlled trial of Zephyr® endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med, 2018; 198(9), 1151-1164.
  2. Emphysema. MedlinePlus. https://medlineplus.gov/emphysema.html. Published May 17, 2018. Accessed June 25, 2018.
  3. Gore et al., How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax, 2000; 55(12), 1000-1006.
  4. Gardiner C, et al., Exploring the care needs of patients with advanced COPD: an overview of the literature. Respiratory Medicine, 2010; 104(2), 159-165.
  5. Vermeire, P, The burden of chronic obstructive pulmonary disease. Respiratory Medicine, 2002; 96, S3-S10.
  6. COPD: Challenging Symptoms, Stigma and Stereotypes Patient Survey Fact Sheet. http://www.emphysema.net/Survey_Fact_Sheet.htm. Accessed Oct. 4 2017.
  7. Granted breakthrough device status (formerly known as the Expedited Access Pathway, or EAP) on May 4, 2017, Summary of Safety and Effectiveness document for the Pulmonx Zephyr Valve system (https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180002B.pdf).
  8. Mansfield C, Sutphin J, Shriner K, Criner GJ, Celli BR. Patient preferences for endobronchial valve treatment of severe emphysema. Chronic Obstr Pulm Dis, 2019; 6(1), 51.
  9. Kemp, SV, Slebos, DJ, Kirk, A, Kornaszewska, M, Carron, K, Ek, L. & Briault, A. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med 2017; 196(12), 1535-1543.
  10. Valipour, A, Slebos, DJ, Herth, F, Darwiche, K, Wagner, M, Ficker, JH, & Eberhardt, R. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study. Am J Respir Crit Care Med 2016; 194(9), 1073-1082.
  11. Klooster, K, ten Hacken, NH, Hartman, JE, Kerstjens, HA, van Rikxoort, EM & Slebos, DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med 2015; 373(24), 2325-2335.
  12. Adapted from Global initiative for Chronic Obstructive Pulmonary Disease (GOLD) Global Strategy for the Diagnosis, Management and Prevention of COPD
  13. Valve Zephyr® (Dispositif médical de Classe II b) CE 086. L’arrêté au journal officiel du 23 avril 2020 portant inscription du système de valves endobronchiques Zephyr au titre III de la liste des produits et prestations remboursables prévue à l’article L.165-1 du code de la sécurité sociale édicte l’indication et les modalités de prescription et d’utilisation prises en charge par les organismes d’assurance maladie.